Table 127Psychoeducation vs. other active treatments

Outcome or SubgroupkTotal NStatsEffect (95% CI)
2.2 Service outcome: 1. Re-hospitalisation (at end of treatment)1RR (M-H, Fixed, 95% CI)Subtotals only
 2.2.1 At end of treatment148RR (M-H, Fixed, 95% CI)Not estimable
2.3 Service Outcome: 1. Re-hospitalisation (at follow up)3RR (M-H, Fixed, 95% CI)Subtotals only
 2.3.1 Up to 12 months FU3308RR (M-H, Fixed, 95% CI)0.90 [0.65, 1.24]
 2.3.2 Up to 12 months FU - Sensitivity analysis removing multimodal studies2184RR (M-H, Fixed, 95% CI)1.00 [0.53, 1.87]
2.6 Global State: 1. Relapse (at follow up)3RR (M-H, Fixed, 95% CI)Subtotals only
 2.6.1 Up to 12 months FU3265RR (M-H, Fixed, 95% CI)0.80 [0.52, 1.24]
2.10 Mental state: 1. Continuous measures - Total symptom score, BPRS, PANSS (lower = better) (at end of treatment)1SMD (IV, Fixed, 95% CI)Subtotals only
 2.10.2 Total symptom score (at end of treatment) (endpt means)148SMD (IV, Fixed, 95% CI)−1.11 [−1.72, −0.50]
2.12 Mental State: 2. Continuous measures - Positive symptom score (PANSS, SAPS) (at end of treatment)4SMD (IV, Random, 95% CI)Subtotals only
 2.12.1 PANSS, SAPS, BPRS positive subscale score (at end of treatment)4260SMD (IV, Random, 95% CI)−0.36 [−0.96, 0.24]
2.13 Mental State: 2. Continuous measures - Positive symptom score (PANSS, SAPS) (at FU)2SMD (IV, Random, 95% CI)Subtotals only
 2.13.1 PANSS, SAPS, BPRS positive subscale score (up to 12 months FU)2162SMD (IV, Random, 95% CI)−0.43 [−1.18, 0.32]
2.14 Mental State: 3. Continuous measures - Negative symptom score (PANSS, SANS) (at end of treatment)4SMD (IV, Fixed, 95% CI)Subtotals only
 2.14.1 PANSS, SANS, BPRS negative subscale (At end of treatment)4260SMD (IV, Fixed, 95% CI)−0.38 [−0.63, −0.13]
2.15 Mental State: 3. Continuous measures - Negative symptom score (PANSS, SANS) (at FU)2SMD (IV, Random, 95% CI)Subtotals only
 2.15.1 PANSS, SANS, BPRS negative subscale (up to 12 months FU)2162SMD (IV, Random, 95% CI)−0.50 [−1.67, 0.66]
2.20 Psychosocial functioning: 1. Social Functioning Schedule (SFS, lower = better) (at end of treatment)1SMD (IV, Fixed, 95% CI)Subtotals only
 2.20.1 Total Score (At end of treatment)128SMD (IV, Fixed, 95% CI)0.95 [0.16, 1.74]
2.26 Psychosocial Functioning: 2. Social disability Screening Schedule (at end of treatment)1SMD (IV, Fixed, 95% CI)Subtotals only
 2.26.1 Total score (At end of treatment)196SMD (IV, Fixed, 95% CI)−0.91 [−1.33, −0.49]
2.27 Psychosocial Functioning: 2. Social disability Screening Schedule (at FU)1SMD (IV, Fixed, 95% CI)Subtotals only
 2.27.1 Total score (up to 6 months FU)193SMD (IV, Fixed, 95% CI)−1.32 [−1.77, −0.87]
2.50 Leaving the study early (at end of treatment)3RR (M-H, Fixed, 95% CI)Subtotals only
 2.50.1 At end of treatment3218RR (M-H, Fixed, 95% CI)0.75 [0.46, 1.23]
 2.50.2 At end of treatment - Sensitivity analysis removing multimodal studies3218RR (M-H, Fixed, 95% CI)0.75 [0.46, 1.23]
2.51 Leaving the study early (at FU)2RR (M-H, Fixed, 95% CI)Subtotals only
 2.51.1 up to 12 months FU2184RR (M-H, Fixed, 95% CI)0.87 [0.41, 1.86]
 2.51.2 up to 24 months FU188RR (M-H, Fixed, 95% CI)0.88 [0.56, 1.37]

From: 10, Clinical evidence summary tables

Cover of Schizophrenia
Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update) [Internet].
NICE Clinical Guidelines, No. 82.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2009 Mar.
Copyright © 2009, National Collaborating Centre for Mental Health.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.